Article Details
Retrieved on: 2024-12-28 09:34:42
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article highlights Sensorion SAS's progress in biotech, specifically in audiology and otology, with its clinical trials for SENS-501 targeting congenital hearing loss. The study focuses on young patients, and excludes those with cochlear implants, to better assess therapy benefits.
Article found on: markets.businessinsider.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here